Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ZURA vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAMP Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–3 Matrix Metrics)

CAMP Overall Winner 6-Pillar Tally: ZURA 1 – 4 CAMP (1 Tie) Matrix Metrics: ZURA 3 – 4 CAMP

As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ZURA carries a Unified Composite Score of 46.3/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin).

  • Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 43.9/100 HOLD), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ZURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZURA vs CAMP
ZURA NASDAQ
Zura Bio Limited Class A Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.01
-6.02% 1D
Market Cap $119.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.55β · 272% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 45.0 Fund 58.0 Flow 70.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 25
RSI-14: 24.8 · SMA20: $2.98 · SMA50: $3.81
CAMP NASDAQ Head-to-Head Winner
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (ZURA 1 – 4 CAMP)

Columns: Metric · ZURA · CAMP
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 26.6x
2. Growth & Scale CAMP
Revenue Growth (YoY) +0.0% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $5.3M
Market Cap $119.4M $238.5M
3. Profitability & Quality ZURA
Gross Margin N/A N/A
Operating Margin 0.0% -991.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.2% -146.1%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$82M -$26M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.84 Book/Sh · -63.2% ROE $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAMP
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 0.2% (<1st %ile) N/A (N/A)
Put/Call OI Skew 1.51x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZURA (3) vs CAMP (4)
Institutional Metric ZURA CAMP Criterion Row Edge
Market Capitalization
Scale
$119.4M $238.5M Larger Scale CAMP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
0.0% -991.8% Higher Margin ZURA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.2% -146.1% Higher ROE ZURA
52-Week Range Position
Momentum
1% ($1–$7) 22% ($3–$8) Stronger Trend CAMP
Beta / 30D Volatility
Risk Regime
0.55β · 272% Vol 1.34β · 94% Vol Lower Realized Risk CAMP
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite ZURA
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$82M ($1.84 Book/Sh · -63.2% ROE) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +99.16 pp
ZURA: -73.36% · CAMP: +25.8%
3M Horizon CAMP +67.57 pp
ZURA: -82.62% · CAMP: -15.05%
6M Horizon CAMP +69.74 pp
ZURA: -74.56% · CAMP: -4.82%
1Y Horizon CAMP +71.46 pp
ZURA: -75.12% · CAMP: -3.66%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZURA vs CAMP. Trailing 12-month operating profitability (ZURA 0.0% vs CAMP -991.8%) and valuation multiples (ZURA N/M vs CAMP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.2% · N/M
CAMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross MarginN/A
Op. Margin-991.8%
ROE / Fwd P/E-146.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZURA BREAKDOWN
59d in phase · OBV DISTRIBUTION
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew 1.51x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ZURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $119.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZURA vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ZURA carries a Unified Composite Score of 46.3/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin). Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 43.9/100 HOLD), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY). Technical & Structure Timing Caution: ZURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: ZURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). On trailing 12-month operating scale, ZURA generates N/A in USD-normalized revenue versus $5.3M for CAMP. In operating R&D and SG&A reinvestment, ZURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

CAMP screens cheaper on headline valuation multiples. ZURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZURA (-63.2% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ZURA carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 1.51x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.55β · 272% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.